Premium
Pharmacokinetics and bio‐distribution of novel super paramagnetic iron oxide nanoparticles ( SPION s) in the anaesthetized pig
Author(s) -
Edge Deirdre,
Shortt Christine M,
Gobbo Oliviero L,
Teughels Stephanie,
PrinaMello Adriele,
Volkov Yuri,
MacEneaney Peter,
Radomski Marek W,
Markos Farouk
Publication year - 2016
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.12533
Subject(s) - biocompatibility , biodistribution , pharmacokinetics , chemistry , nanoparticle , iron oxide nanoparticles , nuclear chemistry , materials science , pharmacology , nanotechnology , medicine , biochemistry , in vitro , organic chemistry
Summary Manufactured nanomaterials have a variety of medical applications, including diagnosis and targeted treatment of cancer. A series of experiments were conducted to determine the pharmacokinetic, biodistribution and biocompatibility of two novel magnetic nanoparticles ( MNP s) in the anaesthetized pig. Dimercaptosuccinic acid ( DMSA ) coated superparamagnetic iron oxide nanoparticles ( MF 66‐labelled 12 nm, core nominal diameter and OD 15 15 nm); at 0.5, or 2.0 mg/kg) were injected intravenously. Particles induced a dose‐dependent decrease in blood pressure following administration which recovered to control levels several minutes after injection. Blood samples were collected for a 5‐h period and stored for determination of particle concentration using particle electron paramagnetic resonance ( pEPR ). Organs were harvested post‐mortem for magnetic resonance imaging ( MRI at 1.5 T field strength) and histology. OD 15 (2.0 mg/kg) MNP had a plasma half‐life of approximately 15 min. Both doses of the MF 66 (0.5 and 2.0 mg/kg) MNP were below detection limits. MNP accumulation was observed primarily in the liver and spleen with MRI scans which was confirmed by histology. MRI also showed that both MNP s were present in the lungs. The results show that further modifications may be required to improve the biocompatibility of these particles for use as diagnostic and therapeutic agents.